Cited by 843Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Open access

Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin·2017·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2016.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Introduction We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.Methods Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided.Results In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03).Conclusion In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.10.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Flagged first, then by citations

Show all 15 references

Sorted by citations

Items 401–500 of 843

Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Lim, S. M., Kim, S.-W., Cho, B. C., Kang, J., Ahn, M., Kim, D., Kim, Y., Lee, J. S., Lee, J.-S., Lee, S. Y., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.245 · Cited by 15
T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs)
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14870 · Cited by 16
A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation
Oguri, T., Sasada, S., Seki, S., Murata, S., Tsuchiya, Y., Ishioka, K., Takahashi, S., Seki, R., Hirose, S., Katayama, R., et al. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101405 · Cited by 15
Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer
Geng, D., Guo, Q., Huang, S., Zhang, H., Guo, S., & Li, X. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02701-x · Cited by 15
Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
Long, Y., Xiong, Q., Song, Q., Li, Y., Li, X., Qin, B., Huang, Z., Hu, Y., & Yang, B. Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14271 · Cited by 16
Oncogene Addicted Non-Small-Cell Lung Cancer: Current Standard and Hot Topics
Vecchiarelli, S., & Bennati, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0095 · Cited by 17
Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
Heigener, D. F., Kerr, K. M., Laing, G. M., Mok, T. S. K., Moiseyenko, F. V., & Reck, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1894 · Cited by 16
Self-citation
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution
Salati, M., Baldessari, C., Cerbelli, B., & Botticelli, A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.01.14 · Cited by 15
Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer: Is There Room for Reinvestigation?
Ahn, M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.005 · Cited by 15
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma
Li, S. D., Martial, A. M., Schrock, A. B., & Liu, J. J. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0089-y · Cited by 14
Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
Saw, S. P. L., Ang, M., & Tan, D. S. W. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01034-3 · Cited by 14
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
Zhong, H., Zhang, X., Tian, P., Chu, T., Guo, Q., Yu, X., Yu, Z., Li, Y., Chen, L., Liu, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006887 · Cited by 17
Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
Dong, Y., Khan, L., & Yao, Y. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.06.004 · Cited by 14
Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy
Liao, S., Sun, H., Lu, H., Wu, J., Wu, J., Wu, Z., Xi, J., Liao, W., & Wang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-13811-y · Cited by 14
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment
Passiglia, F., Caglevic, C., Giovannetti, E., Pinto, J. A., Manca, P., Taverna, S., Listì, A., Bazo, I. G., Raez, L., Russo, A. D., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.015 · Cited by 15
The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective
Young, K., Santos, G. D. C., Card, P. B., & Leighl, N. B. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22085 · Cited by 14
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Chen, J. A., & Riess, J. W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00750-y · Cited by 14
Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sun, F., & McCoach, C. E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00867-8 · Cited by 14
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
Farnsworth, D., Chen, Y. T., de Rappard-Yuswack, G., & Lockwood, W. W. (2021) · Cells · doi:10.3390/cells10123553 · Cited by 16
Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
Li, Y., Hu, L., Peng, X., Xu, H., Tang, B., & Xu, C. S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.102 · Cited by 13
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
Su, P., Chen, J., Chu, C., Chen, Y., Chen, W.-L., Lin, K., Ho, C., Tsai, J., Yang, S., Chen, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07423-w · Cited by 14
Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
Bodor, J. N., Bauman, J. R., Handorf, E. A., Ross, E. A., Clapper, M. L., & Treat, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04089-9 · Cited by 14
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
Suda, K., Rozeboom, L. M., Furugaki, K., Yu, H., Melnick, M. A., Ellison, K. E., Rivard, C. J., Politi, K. A., Mitsudomi, T., & Hirsch, F. R. (2017) · BioMed Research International · doi:10.1155/2017/7694202 · Cited by 14
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
Shafique, M. R., Robinson, L. A., & Antonia, S. J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s148009 · Cited by 14
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 15
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor
Bang, Y. H., Park, G., Oh, J. W., Hwang, S., Jeong, J.-G., Lee, B., Joe, C. Y., Kim, H. M., Kim, J., Park, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012374 · Cited by 13
MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
Bai, L., Huo, R., Fang, G., Ma, T., & Shang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1055122 · Cited by 13
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer
Reyes, A., Muddasani, R., & Massarelli, E. (2024) · Cancers · doi:10.3390/cancers16162919 · Cited by 14
Efficacy and safety of osimertinib in a Japanese compassionate use program
Fujiwara, Y., Goto, Y., Kanda, S., Horinouchi, H., Yamamoto, N., Sakiyama, N., Makihara, R. A., & Ohe, Y. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx050 · Cited by 13
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
Sekine, A., & Satoh, H. (2017) · Medical Oncology · doi:10.1007/s12032-017-0978-2 · Cited by 13
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors
Heigener, D. F., & Reck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.112 · Cited by 13
Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer
Lim, J. U. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.07.015 · Cited by 14
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
Hong, L., Lewis, W. E., Nilsson, M. B., Patel, S. A., Varghese, S., Rivera, M. J., Du, R. R., Chen, P., Kemp, H. N., Rinsurongkawong, W., et al. (2022) · Cancers · doi:10.3390/cancers14143473 · Cited by 13
Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
Zhao, G., Zhang, H., Xu, F., Lu, C., Zhu, Q., Grossi, F., Divisi, D., Ma, T., Gu, J., & Ge, D. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-871 · Cited by 15
Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells
Letian, A., Lemma, E. Y., Cavaliere, P., Dephoure, N., Altorki, N. K., & McGraw, T. E. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01084-6 · Cited by 13
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
Sato, M., Watanabe, S., Tanaka, H., Nozaki, K., Arita, M., Takahashi, M., Shoji, S., Ichikawa, K., Kondo, R., Aoki, N., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215292 · Cited by 14
Management of CNS metastases in patients with EGFR mutation-positive NSCLC
Shetty, V. V., & Suresh Babu, M. C. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_455_19 · Cited by 13
Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms
Sun, Y. H., Shao, C., Duan, H., Wang, Z., Xu, S., Wang, C., Xiu, J., Liu, J., Wang, X., Yao, X., et al. (2025) · MedComm · doi:10.1002/mco2.70496 · Cited by 15
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
Qiao, M., Zhou, F., Liu, X., Jiang, T., Wang, H., Jia, Y., Li, X., Zhao, C., Cheng, L., Chen, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005436 · Cited by 15
Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 13
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
Yan, D. (2023) · Biomedicines · doi:10.3390/biomedicines11112916 · Cited by 12
SIRT5 participates in the suppressive tumor immune microenvironment of EGFR-mutant LUAD by regulating the succinylation of ACAT1
Shouhan, W., Li, Q., & Xiaodan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39743 · Cited by 12
The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
Jean, F., Tomasini, P., & Barlési, F. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017741074 · Cited by 12
Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape
Xia, W. G., Mao, W., Chen, R., Lu, R., Liu, F., He, Y., Wang, S., Li, X., & Zheng, M. (2019) · Medical Science Monitor · doi:10.12659/msm.920042 · Cited by 13
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer
Le, X., & Heymach, J. V. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0760 · Cited by 13
Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
Chen, Q., Shang, X., Liu, G., Ma, X., Han, W., Wang, X., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931718 · Cited by 12
Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin
Feng, Y., Huo, H., & Tang, Q. (2022) · Journal of Oncology · doi:10.1155/2022/5308577 · Cited by 13
E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis
Chang, Y.-P., Huang, G.-K., Chen, Y., Huang, K., Chen, Y., Lin, C.-Y., Huang, C., Lin, M., & Wang, C. (2023) · BMC Cancer · doi:10.1186/s12885-023-10980-6 · Cited by 12
Tumor-associated macrophages—additional effectors at anti-PD-1/PD-L1 therapy?
Suda, K. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.15 · Cited by 12
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer
Hegde, A. M., Hong, D. S., Amini, B., Ali, S. M., Juckett, L. T., Meric‐Bernstam, F., & Subbiah, V. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00267 · Cited by 12
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
Sartori, G., Belluomini, L., Lombardo, F., Avancini, A., Trestini, I., Vita, E., Tregnago, D., Menis, J., Bria, E., Milella, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1776119 · Cited by 12
Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Guo, X., Du, H., Li, J., Yang, M., Xiong, A., Zhang, H., & Wu, F. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.85 · Cited by 12
Neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Xie, H., Shi, X., & Wang, G. (2021) · PubMed · Cited by 16
Combination of radiotherapy and PD-L1 blockade induces abscopal responses in EGFR-mutated lung cancer through activating CD8+ T cells
Xia, W.-Y., Shen, Y.-J., Zhang, C.-C., Qian, L., Wang, H., Wang, K., Jin, H.-Z., Zhu, X., Ding, Z.-P., Zhang, Q., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102074 · Cited by 12
Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis
Piotrowska, Z., Yeap, B. Y., & Gainor, J. F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103660 · Cited by 13
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy
Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 12
Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression
Mitrakas, A. G., Kakouratos, C., Lamprou, I., Xanthopoulou, E. T., & Koukourakis, M. I. (2025) · Cancers · doi:10.3390/cancers17050853 · Cited by 14
Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
Kapoor, S. S., & Zaiss, D. M. W. (2021) · Biomedicines · doi:10.3390/biomedicines10010052 · Cited by 11
Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer
Tang, M., Lee, C. K., Lewis, C. R., Boyer, M. J., Brown, B. B., Schaffer, A. L., Pearson, S., & Simes, R. J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.024 · Cited by 11
Self-citation
The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
Chen, Y., Su, P., Huang, W., Chang, C., Yen, Y., Lin, C., & Tseng, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-22957-9 · Cited by 12
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study
Zhou, C., Wang, Z., Fu, C., Tao, H., & Liu, C. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6272 · Cited by 11
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective
Pasello, G., Scattolin, D., Bonanno, L., Caumo, F., Dell’Amore, A., Scagliori, E., Tinè, M., Calabrese, F., Benati, G., Sepulcri, M., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102544 · Cited by 11
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study
Araki, T., Kanda, S., Obara, M., Agatsuma, T., Kakizaki, Y., Hama, M., Yamamoto, H., Takada, M., Yamamoto, M., Matsuo, A., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.002 · Cited by 11
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer
Izumi, H., Yamasaki, A., Takeda, K., Kodani, M., Touge, H., Tanaka, N., Yanai, M., Ueda, Y., Sakamoto, T., Nishii‐Ito, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.022 · Cited by 11
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.08 · Cited by 10
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
Zhao, D., Mambetsariev, I., Li, H., Chen, C., Fricke, J., Fann, P., Kulkarni, P., Xing, Y., Lee, P. P., Bild, A., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.025 · Cited by 11
Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer
Zhong, R., Xu, J., Lou, Y., Chu, T., Zhong, H., & Han, B. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-105 · Cited by 11
Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
Codony‐Servat, J., García-Román, S., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Viteri, S., d'Hondt, E., & Rosell, R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100887 · Cited by 11
Immunotherapy in lung cancer
Bravo, G. L., Farid, S., & Liu, S. V. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26347 · Cited by 11
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma
Qi, Y. A., Maity, T. K., Gao, S., Gong, T., Bahta, M., Venugopalan, A. K., Zhang, X., & Guha, U. (2021) · Cancers · doi:10.3390/cancers13194977 · Cited by 14
Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation
Lee, I.-H., Yang, C., Shih, J., & Yu, C. (2021) · Biomedicines · doi:10.3390/biomedicines9101416 · Cited by 11
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives
Tang, Z., Zha, L., Liang, R., & Li, T. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01778-7 · Cited by 11
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
Ferro, A., Filoni, A., Pavan, A., Pasello, G., Guarneri, V., Conte, P., Alaibac, M., & Bonanno, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.570921 · Cited by 10
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
Li, Y.-S., Jie, G., & Wu, Y.-L. L. C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231193726 · Cited by 10
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Dai, Y., Tian, X., Ye, X., Gong, Y., Xu, L., & Jiao, L. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.166 · Cited by 14
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Saw, S. P. L., Zhong, W., Fu, R., Li, M. S. C., Goto, Y., Fox, S. B., Yatabe, Y., Ong, B., Ng, C. S. H., Lee, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2024.108076 · Cited by 10
Self-citation
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
Zhang, W., Xia, H., Yang, R. R., Zhang, Y., Zheng, Q., Shang, X., Liu, N., Ma, X., Wei, C., Chen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030969 · Cited by 10
Biomarkers of immunotherapy for non-small cell lung cancer
Shirasawa, M., Yoshida, T., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad134 · Cited by 10
Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma
Gong, Z., Chen, J., Cheng, J., Sun, C., Jia, Q., Diao, X., & Zhu, B. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.011 · Cited by 10
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer—Towards Daily Practice
Domagala-Kulawik, J. J. (2018) · Advances in respiratory medicine · doi:10.5603/arm.2018.0022 · Cited by 10
Lung spindle cell carcinoma harbouring a constitutively active epidermal growth factor receptor mutation
Ikushima, H., Sakatani, T., Masuda, Y., Morikawa, T., & Usui, K. (2018) · Respirology Case Reports · doi:10.1002/rcr2.395 · Cited by 10
Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells
Li, T., Zhang, F., Qin, P., Wang, Y., Wang, A., Zhao, L., Xu, B., & Gao, Q. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00113 · Cited by 10
A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
Watanabe, H., Ohashi, K., Nishii, K., Seike, K., Makimoto, G., Hotta, K., Maeda, Y., & Kiura, K. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2875-19 · Cited by 10
Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis
Hakozaki, T., Okuma, Y., Hashimoto, K., & Hosomi, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02985-1 · Cited by 10
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
Kibirova, A., Mattes, M. D., Smolkin, M. B., & Ma, P. C. (2019) · Case Reports in Oncology · doi:10.1159/000503417 · Cited by 10
Immunotherapy in oncogene addicted non-small cell lung cancer
McLean, L. S., Leal, J. L., Solomon, B., & John, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-772 · Cited by 11
Modeling Resistance and Recurrence Patterns of Combined Targeted–Chemoradiotherapy Predicts Benefit of Shorter Induction Period
McClatchy, D. M., Willers, H., Hata, A. N., Piotrowska, Z., Sequist, L. V. D., Paganetti, H., & Grassberger, C. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3883 · Cited by 10
Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma
Chen, S., Duan, H., Xie, Y., Li, X., & Zhao, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2113 · Cited by 10
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
Veccia, A., Dipasquale, M., Kinspergher, S., Monteverdi, S., Girlando, S., Barbareschi, M., & Caffo, O. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00934-6 · Cited by 10
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
Wang, H., Chen, S., Meng, D., Wu, C., Zhu, J., Jiang, M., Ning, J., Wu, S., Wu, L., Li, J., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s294993 · Cited by 10
ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
Zhang, W., Shang, X., Liu, G., Ma, X., Yang, R. R., Xia, H., Zhang, Y., Zheng, Q., Wang, X., & Liu, Y. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02279-2 · Cited by 9
Perioperative Immunotherapy in Non-Small Cell Lung Cancer
O'Brien, J. A., & Bodor, J. N. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01160-6 · Cited by 9
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 9
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC
Zhang, W., Wang, J., Liang, J., He, Z., Wang, K., & Lin, H. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02945-2 · Cited by 9
EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC
Zhou, Z., Chen, S. E., Zhao, J., Du, X., Yin, H., Zhou, C., Hu, H., Yu, Y., Zhu, Y., & Yao, H. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102199 · Cited by 10
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction
Wu, F., Shen, J., Zhao, Z., Chen, Y., Ren, B., Li, M., Yin, R. H., Zhang, Y., & Yu, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218219 · Cited by 9
Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
Fischer, A., Bankel, L., Hiltbrunner, S., Rechsteiner, M., Rüschoff, J. H., Rushing, E. J., Britschgi, C., & Fontecedro, A. C. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00918-6 · Cited by 9
EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Kim, H.-S., Park, S., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., & Ahn, M. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.388 · Cited by 9

Authors: Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H.
Affiliations: The University of Sydney (AU)
St George Hospital (AU)
Chinese University of Hong Kong (HK)
National Taiwan University (TW)
Corresponding author: Lee, Chee Khoon
ORCID: Lee, Chee Khoon
Man, Johnathan
Links, Matthew
Gebski, Val
Mok, Tony
Yang, James Chih-Hsin
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2017-02
Volume: 12
Issue: 2
Pages: 403-407
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2016.10.007
OpenAlex: W2538232731
Cited by: 839
References: 15
Citations by year: 2026: 47 · 2025: 61 · 2024: 68 · 2023: 84 · 2022: 93 · 2021: 98 · 2020: 100 · 2019: 100 · 2018: 123 · 2017: 62
FWCI: 85.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, second-line therapy, nivolumab, pembrolizumab, atezolizumab, docetaxel, overall survival, advanced non-small cell lung cancer
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Mutation, Prognosis, Randomized Controlled Trials as Topic, Cell Cycle Checkpoints, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks